The interplay between pre-season population susceptibility and the effectiveness of the rolled out vaccination control the timing and size of an emerging seasonal influenza wave in England

Relaxing social distancing measures and reduced level of influenza over the last two seasons may lead to a winter 2022 influenza wave in England. We used an established model for influenza transmission and vaccination to evaluate the rolled out influenza immunisation programme over October to December 2022. Specifically, we explored how the interplay between pre-season population susceptibility and influenza vaccine efficacy control the timing and the size of a possible winter influenza wave. Our findings suggest that susceptibility affects the timing and the height of a potential influenza wave, with higher susceptibility leading to an earlier and larger influenza wave while vaccine efficacy controls the size of the peak of the influenza wave. With pre-season susceptibility higher than pre-COVID-19 levels, under the planned vaccine programme an early influenza epidemic wave is possible, its size dependent on vaccine effectiveness against the circulating strain. If pre-season susceptibility is low and similar to pre-COVID levels, the planned influenza vaccine programme with an effective vaccine could largely suppress a winter 2022 influenza outbreak in England.

[1]  E. Lau,et al.  Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic: a modelling study , 2022, The Lancet Global Health.

[2]  I. Barr,et al.  Is the UK prepared for seasonal influenza in 2022–23 and beyond? , 2022, The Lancet Infectious Diseases.

[3]  M. Baguelin,et al.  Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis , 2022, Vaccine.

[4]  V. Colizza,et al.  The missing season: The impacts of the COVID-19 pandemic on influenza , 2021, Vaccine.

[5]  M. Halloran,et al.  Cost-effectiveness of live-attenuated influenza vaccination among school-age children. , 2020, Vaccine.

[6]  S. de Lusignan,et al.  End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  Marc Baguelin,et al.  fluEvidenceSynthesis: An R package for evidence synthesis based analysis of epidemiological outbreaks , 2017, PLoS Comput. Biol..

[8]  R. Pebody,et al.  Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere , 2017, Archives of Disease in Childhood.

[9]  Nicholas S. Kelley,et al.  Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. , 2016, The Lancet. Infectious diseases.

[10]  W. John Edmunds,et al.  Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study , 2013, PLoS medicine.